STAT+: Takeda’s narcolepsy drug approved by the FDA, seen as a boon for new class of treatments
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- FDA approved Takeda's Orzeyful on Wednesday, a twice-daily orexin receptor agonist pill, for narcolepsy type 1 — a condition caused by orexin neuron deficiency that triggers daytime sleepiness and muscle weakness
- Orzeyful helped patients stay awake during the day for much longer than current therapies in two Phase 3 trials, with participants reporting less daytime sleepiness, less frequent muscle weakness, and greater attentiveness
- Takeda's drug targets a fundamentally different mechanism than existing narcolepsy treatments — stimulants and sodium oxybates — which carry misuse risk and still leave patients feeling sleepy
- Orexin receptor agonists could transform treatment of sleep disorders and potentially address a broad range of neurologic conditions, according to scientists cited in the coverage
- Narcolepsy type 1 patients currently rely on stimulants and sodium oxybates, both of which leave residual symptoms and carry documented abuse potential
Why it matters: Narcolepsy type 1 patients gain a non-stimulant, non-oxybate oral option that outperformed today's standard of care in two Phase 3 trials on daytime wakefulness, sleepiness, and muscle weakness — potentially the first mechanistic advance in narcolepsy treatment in decades and a proof-of-concept for the broader orexin agonist class across neurologic conditions.
